Ozempic can change your body. A new study asks whether it changes your life
What happened
A new piece of research has asked a question that most studies of weight loss drugs skip over. Not do these drugs improve health, but do they improve life? The work was released on 17 September 2026 as a working paper by the National Bureau of Economic Research, a respected American research organisation. It was written by Robert Kaestner, an economist at the University of Chicago Harris School of Public Policy, with his co-author Cuiping Schiman. The drugs in question are GLP-1 medicines. You may know them by brand names such as Ozempic, Wegovy or Mounjaro. They were first developed for type 2 diabetes. They also cause substantial weight loss, which is why they have become so widely talked about. The researchers used a large American survey called the Medical Expenditure Panel Survey. It covers the years 2012 to 2023. Its useful feature is that it follows the same individuals over roughly two years, rather than taking a snapshot of different people at one moment. They focused on adults with diabetes. Then they looked at what happened to people's mental health, their employment, their marital status and their general sense of wellbeing after starting a GLP-1 medicine. The answer was: not very much that they could detect.
Why this matters
A lot of the public conversation about these medicines has quietly expanded beyond health. The suggestion, sometimes stated and sometimes just implied, is that losing a significant amount of weight will improve almost everything. Confidence. Mood. Energy. Job prospects. Relationships. The drug is presented not just as a treatment but as a fresh start. That is a big promise, and it has rarely been tested properly. This study is one of the first serious attempts to test it. It matters because expectation shapes experience. Someone who begins a medicine believing it will transform their whole life may feel that it has failed them when it only does what it was designed to do, which is to improve blood sugar, weight and heart risk. Those are real benefits. They are just not the same as happiness. It also matters for money. These drugs are expensive, and health systems including the NHS have to decide who gets them. If claims about wider social benefits are used to argue for wider prescribing, those claims should be supported by evidence. And it matters for anyone weighing up whether to start. Knowing honestly what a treatment does, and does not, tend to do is part of making a real choice.
What the evidence actually says
The central finding is a careful one, and it rests on how the study was designed. If you simply compare people taking GLP-1 drugs with people who are not, differences do appear. Users looked different on things like employment and marriage. But those differences largely vanished once the researchers looked at changes within the same person over time. In other words, the apparent gaps were mostly telling us about what kind of people tend to be prescribed these medicines, rather than about what the medicines do. That is a well-known trap in health research, and avoiding it is the main strength of this study. People who get prescribed a newer, costlier drug often differ from those who do not, in income, in access to healthcare, in how much contact they have with doctors. Following the same individuals over time strips a lot of that out. As Kaestner put it: "We know these drugs improve health outcomes, and there's been a great deal of research documenting those benefits. What hadn't really been examined was whether those improvements extended into other parts of people's lives." Note what he is not saying. He is not saying the drugs do not work. The physical benefits are well established and are not in dispute here. Now the limitations, and they are real. This is a working paper. That means it has not yet been through peer review, the process where independent experts check the methods before publication in a journal. Working papers are shared early so other researchers can scrutinise them. Some change substantially before they are published. This one should be treated as a strong signal, not a settled conclusion. The follow-up period was about two years. Life changes such as finding work or a relationship can take longer than that. An effect that is slow to appear might simply not show up yet. The study looked at adults with diabetes in the United States. People taking these drugs mainly for weight loss, in a different health system, might not be the same. And findings on averages do not describe individuals. That an effect is not detectable across a large group does not mean nobody experienced one. It is also worth saying that other research points in different directions. Some studies have reported mental health benefits from GLP-1 medicines, particularly for specific groups. The overall picture across the field is genuinely mixed rather than settled, and anyone who tells you it is clear-cut is ahead of the evidence.
Practical advice
If you are taking a GLP-1 medicine, or thinking about it, a few things follow from this. Be clear with yourself about what you are hoping for. If the goal is better blood sugar, lower weight and reduced risk to your heart, the evidence supports that. If the goal is to feel differently about your life, that is a separate question, and this medicine may not be the answer to it. That is not a reason to avoid treatment. It is a reason to keep other support in place alongside it rather than expecting the tablet or injection to do everything. If your mood is low, treat that as its own issue worth addressing in its own right. Talk to your GP. In England you can also refer yourself to NHS Talking Therapies without going through a doctor. Weight loss is not a treatment for depression, and waiting for one to fix the other can mean months lost. If you are already on one of these medicines and feel disappointed, you are not failing at it. Much of what was promised in public was never evidence based. Keep up the parts that are known to help regardless of medication: movement you can sustain, sleep, food you actually enjoy, and contact with other people. Do not stop a prescribed medicine because of a news story, including this one. If you want to review whether it is still right for you, book that conversation rather than simply stopping. And be wary of anywhere selling these drugs on the promise of a new life. That promise is not supported by this research, and reputable prescribers do not make it.
What to know
A new working paper from the University of Chicago followed the same American adults with diabetes over time, using data from 2012 to 2023, and found little evidence that GLP-1 medicines such as Ozempic improved mental health, employment, marriage or overall wellbeing. Apparent differences between users and non-users largely disappeared once researchers tracked changes within individuals, suggesting those gaps reflected who gets prescribed the drugs rather than what the drugs do. The physical benefits of these medicines, for blood sugar, weight and heart health, are not in question and were not challenged by this study. The paper has not yet been peer reviewed, followed people for only about two years, and comes from the American health system. Other studies have found mental health benefits, so the wider picture remains unsettled. The sensible takeaway is modest: these are effective medicines for specific physical problems, not a shortcut to a different life. Sources: National Bureau of Economic Research working paper by Robert Kaestner and Cuiping Schiman, 17 September 2026, https://www.nber.org ; ScienceDaily, "Ozempic can change your body. Can it change your life?", 17 September 2026, https://www.sciencedaily.com/releases/2026/09/260917003728.htm ; University of Chicago Harris School of Public Policy, https://harris.uchicago.edu This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional.
Related articles
Six hours, not never: the ICU filter notice the MHRA issued today
The UK's medicines and devices regulator has issued a new safety notice to hospitals, and it is about timing. On 13 October 2026 the Medicines and Healthcare p…
Eight pages to a minister: what the data guardian says trust is worth
On 12 October 2026, the government published a letter about who should be trusted with NHS patient data. It was written by Dr Nicola Byrne, the National Data G…
Update: the tests came back, and it was not plague
This is a follow-up to a story we covered on 5 October, when nearly 200 people were being monitored after the death of a laboratory worker in Siberia. There has…